Eribulin nontaxane microtubule dynamics inhibitor

ER-86526 - ER 086526 - ER086526 - ER-086526 - B-1793 - B 1793 - NSC-707389 - NSC707389 - NSC 707389 - Halaven - E-7389 - E 7389 - B-1939 - B 1939



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - nontaxane microtubule dynamics inhibitor in all type of patients

Trial 301 (Kaufman), 2015eribulincapecitabine1102 (554/548) Confirmatory - NCT00337103
Vahdat, 2013eribulinixabepilone104 (52/52) Exploratory NCT00879086
NCT02037529 ongoing eribulinpaclitaxel910 Confirmatory - NCT02037529
EMBRACE (Cortes), 2011eribulintreatment of physician762 (508/254) Confirmatory - NCT00388726
E7389-C086-304 ongoing eribulinvinorelbineNA Exploratory NCT02225470
SCRI BRE 197 ongoing eribulin+cyclophosphamidedocetaxel+cyclophosphamideNA NCT01527487
2014-0857 ongoing eribulin+gemcitabinepaclitaxel+gemcitabineNA Exploratory NCT02263495